AstraZeneca PLC — Regulatory Filings 2020

Mar 12, 2020

6-K 1 a8387f.htm NOTICE OF AGM Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2020 Issuer Direct Corporation a8387f

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2020

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Notice of AGM

12 March 2020 11:00 GMT

Notice of Annual General Meeting

AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2020 and Shareholders' Circular (the Notice).

The Notice has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The Notice is also available on the Company's website at www.astrazeneca.com/agm .

The Company's Annual Report and Form 20-F Information 2019 was published on 3 March 2020.

The Notice is being despatched to shareholders today.

The meeting place for the Annual General Meeting (AGM) will be Leonardo Royal Hotel London Tower Bridge, 45 Prescot St, London, E1 8GP and the AGM will commence at 2.30 pm (BST) on 29 April 2020.

The Company continues to monitor the situation in relation to COVID-19 and will notify shareholders via our website, www.astrazeneca.com as soon as practicably possible if there are any changes to the AGM arrangements. Shareholders are reminded of their right to appoint the Chairman of the AGM, or any other person, as their proxy to attend the meeting and vote on their behalf.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

| Media Relations — Gonzalo
Viña | | +44 203 749 5916 |
| --- | --- | --- |
| Rob
Skelding | Oncology | +44 203 749 5821 |
| Rebecca
Einhorn | Oncology | +1 301 518 4122 |
| Matt
Kent | BioPharmaceuticals | +44 203 749 5906 |
| Angela
Fiorin | BioPharmaceuticals | +44 1223 344 690 |
| Jennifer
Hursit | Other | +44 203 749 5762 |
| Christina
Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele
Meixell | US | +1 302 885 2677 |
| Investor Relations | | |
| Thomas
Kudsk Larsen | | +44 203 749 5712 |
| Henry
Wheeler | Oncology | +44 203 749 5797 |
| Christer
Gruvris | BioPharmaceuticals (Cardiovascular, Metabolism) | +44 203 749 5711 |
| Nick
Stone | BioPharmaceuticals (Renal) Environmental, Social and
Governance | +44 203 749 5716 |
| Josie
Afolabi | BioPharmaceuticals (Respiratory) | +44 203 749 5631 |
| Tom
Waldron | Other medicines | +44 7385 033 717 |
| Craig
Marks | Finance Fixed income | +44 7881 615 764 |
| Jennifer
Kretzmann | Corporate access Retail investors | +44 203 749 5824 |
| US
toll-free | | +1 866 381 72 77 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 12 March 2020

| By: /s/
Adrian Kemp |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break